Verrica Pharmaceuticals Inc. announced the appointment of Chris Chapman as its Chief Commercial Officer. Chris Chapman brings over 25 years of commercial experience in the pharmaceutical industry to Verrica. Most recently, he served as Chief Commercial Officer at Dermavant Sciences, where he played an instrumental role in launching VTAMA (tapinarof) cream, 1%, approved for adult plaque psoriasis in June 2022 and atopic dermatitis in December 2024.
He was also a key leader in integrating the Dermavant commercial organization with Organon after its acquisition of Dermavant in October 2024. Prior to his roles with Dermavant and Organon, Mr. Chapman served as Vice President & General Manager, U.S. Prescription Business for Galderma, where he led the U.S. Prescription Business. Prior to Galderma, Chris spent 20 years in commercial roles at Pfizer, where he led the U.S. Pharmaceutical Contracting and Pricing Organization.
Mr. Chapman received a Bachelor of Science degree from Towson University.
